12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Prosensa B.V., GlaxoSmithKline deal

Prosensa received £10 million ($16 million) in milestone payments from GlaxoSmithKline under an expanded 2009 deal granting GSK rights to develop and commercialize Duchenne muscular dystrophy (DMD) candidates. Prosensa said it added two additional preclinical compounds - PRO052 and PRO055 - to its DMD pipeline, which now comprises six compounds in development to treat...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >